Although short-acting meglitinides are supposed to offer the advantage of having lower incidence of hypoglycemia, our results showed that the magnitude of the risk in advanced CKD patients was comparable to that of sulfonylurea or insulin. The gene discussed is INS; the disease is chronic kidney disease.